title: Elvitegravir/cobicistat/emtricitabine/tenofovir DF in HIV-infected patients with mild-to-moderate renal impairment.
abstract: In HIV-1-infected treatment-naive patients with mild-to-moderate renal impairment [creatinine clearance (CrCl): 50-89 mL/min], elvitegravir/cobicistat/emtricitabine/tenofovir DF (STB, n = 33) achieved high rates of virologic success (78.8%; 95% confidence interval: 61.1% to 91.0%) and was well tolerated through week 48. Four patients discontinued study drug due to an adverse event and none due to proximal renal tubulopathy. As expected, decreases in CrCl were noted as early as week 2, after which they stabilized. The renal safety profile of STB in patients from this study is consistent with the long-term experience in a large number of patients with CrCl ≥70 mL/min.
authors.affiliation: *Department of HIV Medicine, King's College Hospital, London, United Kingdom; †Department of Medicine, Division of Nephrology, Mount Sinai Hospital, New York, NY; ‡HIV Unit, Hospital Civil de Guadalajara "Fray Antonio Alcalde," Guadalajara, Mexico; §Department of HIV Medicine, Brighton and Sussex Medical School, Brighton, United Kingdom; and ‖Gilead Sciences, Inc., Foster City, CA.
authors.forename: Frank A
authors.initials: FA
authors.lastname: Post
authors.forename: Jonathan
authors.initials: J
authors.lastname: Winston
authors.forename: Jaime F
authors.initials: JF
authors.lastname: Andrade-Villanueva
authors.forename: Martin
authors.initials: M
authors.lastname: Fisher
authors.forename: YaPei
authors.initials: Y
authors.lastname: Liu
authors.forename: Christophe
authors.initials: C
authors.lastname: Beraud
authors.forename: Michael E
authors.initials: ME
authors.lastname: Abram
authors.forename: Hiba
authors.initials: H
authors.lastname: Graham
authors.forename: Martin S
authors.initials: MS
authors.lastname: Rhee
authors.forename: Andrew K
authors.initials: AK
authors.lastname: Cheng
authors.forename: Javier
authors.initials: J
authors.lastname: Szwarcberg
mesh_terms: D000225:Adenine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002219:Carbamates / Q000009:adverse effects / Q000627:therapeutic use; D000069547:Cobicistat; D015331:Cohort Studies; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D000068679:Emtricitabine; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D063065:Organophosphonates / Q000009:adverse effects / Q000627:therapeutic use; D015363:Quinolones / Q000009:adverse effects / Q000627:therapeutic use; D051437:Renal Insufficiency / Q000139:chemically induced* / Q000473:pathology*; D000068698:Tenofovir; D013844:Thiazoles / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D019380:Anti-HIV Agents; D002219:Carbamates; D063065:Organophosphonates; D015363:Quinolones; D013844:Thiazoles; D003841:Deoxycytidine; C509700:elvitegravir; D000068698:Tenofovir; D000068679:Emtricitabine; D000225:Adenine; D000069547:Cobicistat